Journal of Alzheimer s Disease · 2015 · 200 citations · 45 references
MedicineNeurologyNeuroscienceDementiaNeurodegenerationNeuropsychologyAlzheimer DiseaseBiomarkers Of NeurodegenerationCognitive AssessmentCognitive DeclineCognitive ImpairmentDementia BiomarkersAlzheimer Disease ProgressionCognitive BiomarkersCognitive MarkersCognitive StagingDementia StagingNeuroimaging MarkersPreclinical Alzheimer DiseasePreclinical Dementia Biomarkers
The NIA-AA criteria for "preclinical" Alzheimer's disease (AD) propose a staging method in which AD biomarkers follow an invariable temporal sequence in accordance with the amyloid cascade hypothesis. However, recent findings do not align with the proposed temporal sequence and "subtle cognitive decline," which has not been definitively operationalized, may occur earlier than suggested in preclinical AD. We aimed to define "subtle cognitive decline" using sensitive and reliable neuropsychological tests, and to examine the number and sequence of biomarker abnormalities in the Alzheimer's Disease Neuroimaging Initiative (ADNI). 570 cognitively normal ADNI participants were classified based on NIA-AA criteria and separately based on the number of abnormal biomarkers/cognitive markers associated with preclinical AD that each individual possessed. Results revealed that neurodegeneration alone was 2.5 times more common than amyloidosis alone at baseline. For those who demonstrated only one abnormal biomarker at baseline and later progressed to mild cognitive impairment/AD, neurodegeneration alone was most common, followed by amyloidosis alone or subtle cognitive decline alone, which were equally common. Findings suggest that most individuals do not follow the temporal order proposed by NIA-AA criteria. We provide an operational definition of subtle cognitive decline that captures both cognitive and functional decline. Additionally, we offer a new approach for staging preclinical AD based on number of abnormal biomarkers, without regard to their temporal order of occurrence. This method of characterizing preclinical AD is more parsimonious than the NIA-AA staging system and does not presume that all patients follow a singular invariant expression of the disease.
45
Guy M. McKhann, David S. Knopman, Howard Chertkow et al. · Alzheimer s & Dementia · 2011 · 18.8K citations · Full text
Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy
Maj-Linda B. Selenica, Milene L. Brownlow, Jeffy P. Jimenez et al. · Neurodegenerative Diseases · 2012 · 10.4K citations · Full text
Marilyn S. Albert, Steven T. DeKosky, Dennis W. Dickson et al. · Alzheimer s & Dementia · 2011 · 10.2K citations
Reisa A. Sperling, Paul Aisen, Laurel Beckett et al. · Alzheimer s & Dementia · 2011 · 7.1K citations · Full text
Medicine, Neurology, Neuroscience +17
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Clifford R. Jack, David S. Knopman, William J. Jagust et al. · The Lancet Neurology · 2009 · 4.8K citations · Full text